Dec 24 (Reuters) - Shares of Agios Pharmaceuticals (AGIO) jumped 18% on Wednesday after the U.S. Food and Drug Administration approved the expanded use of its drug for the treatment of a type of blood disorder.
The drug mitapivat is now approved as a treatment for patients with anemia in both non-transfusion-dependent and transfusion-dependent alpha- or beta-thalassemia, the company said late on Tuesday.
Thalassemia is an inherited blood disorder affecting the body's ability to produce hemoglobin and healthy red blood cells.
The drug, under the brand name Aqvesme, is expected to be available in late January next year, following the implementation of the required safety program.
Mitapivat was already approved by the U.S. FDA in 2022 to treat low red blood cell counts in adults with pyruvate kinase deficiency, under the brand name of Pyrukynd.
"The approval unlocks an additional $320 million in peak revenue opportunity layered atop the existing mitapivat franchise," Truist analyst Gregory Renza said.
The latest approval is based on a late-stage study in which patients receiving mitapivat showed a statistically significant increase in hemoglobin response compared to those on placebo.
Aqvesme will carry a boxed warning for liver function tests every four weeks during the first 24 weeks of treatment and advises against use in patients with cirrhosis, Renza added.
(Reporting by Siddhi Mahatole in Bengaluru; Editing by Vijay Kishore)
LATEST POSTS
- 1
Public mistrust linked to drop in deceased donor organ donations and kidney transplants - 2Find the Specialty of Public Speaking: Drawing in and Convincing Crowds with Certainty
- 3Favored Organic product for Seniors' Prosperity: Make Your Determination
- 4Yoshi mania, Happy Meals and not-so-great reviews: A small talk guide to 'The Super Mario Galaxy Movie'
- 5Russian military plane crashes in annexed Crimea, killing 29 people on board
- Australia to offer businesses $693 million in cheap loans to ease fuel cost pressure
- US FDA investigates Takeda's blood disorder drug after pediatric death
- ABC News' Sam Champion opens up about recent health scare
- Dominating Capable Mastercard Utilization: Key Contemplations
- Genesis Marks 10th Anniversary With Magma GT Concept Aimed at High-Performance Flagships
- Find the Wonders of the Silk Street: Following the Antiquated Shipping lanes
- West Bank man indicted for extortion, impersonation of IAF pilot, Mossad agent, illegal entry
- Second doctor in Matthew Perry overdose case sentenced to home confinement
- Jupiter and the moon take a sunset stroll on March 26. Here's how to see it
